2.63 USD
-0.14
5.05%
Updated May 14, 1:15 PM EDT
1 day
-5.05%
5 days
-6.07%
1 month
-7.72%
3 months
2.73%
6 months
-6.07%
Year to date
12.88%
1 year
-9.31%
5 years
-95.48%
10 years
-98.54%
 

About: OncoCyte Corp is a pioneering diagnostics technology company. Its mission is to democratize access to novel molecular diagnostic testing to improve patient outcomes. The company develops diagnostic tests based on liquid biopsies using blood or urine samples for detecting lung, bladder, and breast cancers. In addition, it also develops screening diagnostics as potential replacements for screening imaging procedures that do not meet the needs of patients, health care providers, or payers.

Employees: 49

0
Funds holding %
of 7,425 funds
0
Analysts bullish %
of 3 analysts

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

500% more first-time investments, than exits

New positions opened: 6 | Existing positions closed: 1

100% more funds holding in top 10

Funds holding in top 10: 1 [Q3] → 2 (+1) [Q4]

80% more repeat investments, than reductions

Existing positions increased: 9 | Existing positions reduced: 5

25% more funds holding

Funds holding: 20 [Q3] → 25 (+5) [Q4]

2% less capital invested

Capital invested by funds: $20.4M [Q3] → $20M (-$396K) [Q4]

3.63% less ownership

Funds ownership: 53.6% [Q3] → 49.97% (-3.63%) [Q4]

Research analyst outlook

3 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target
$4
52%
upside
Avg. target
$4.42
68%
upside
High target
$5
90%
upside

3 analyst ratings

positive
67%
neutral
33%
negative
0%
Needham
Mike Matson
44% 1-year accuracy
17 / 39 met price target
62%upside
$4.25
Buy
Reiterated
13 May 2025
Lake Street
Thomas Flaten
100% 1-year accuracy
2 / 2 met price target
90%upside
$5
Buy
Initiated
28 Mar 2025
Stephens & Co.
Mason Carrico
15% 1-year accuracy
4 / 27 met price target
52%upside
$4
Equal-Weight
Reiterated
26 Mar 2025

Financial journalist opinion

Based on 9 articles about OCX published over the past 30 days

Neutral
Seeking Alpha
1 day ago
OncoCyte Corporation (OCX) Q1 2025 Earnings Call Transcript
OncoCyte Corporation (NASDAQ:OCX ) Q1 2025 Earnings Conference Call May 12, 2025 5:00 PM ET Company Participants Gabby Woody - Executive Assistant, HR Coordinator Josh Riggs - President & Chief Executive Officer Andrea James - Chief Financial Officer Ekke Schutz - Chief Science Officer Conference Call Participants Mark Massaro - BTIG Mason Carrico - Stephens Thomas Flaten - Lake Street Mike Matson - Needham Yuan Zhi - B. Riley Securities Gabby Woody Welcome everyone and thank you for joining us to discuss OncoCyte's First Quarter 2025 Results.
OncoCyte Corporation (OCX) Q1 2025 Earnings Call Transcript
Neutral
GlobeNewsWire
1 day ago
Oncocyte Reports Q1 2025 Results and Business Progress
IRVINE, Calif., May 12, 2025 (GLOBE NEWSWIRE) -- Oncocyte Corp. (Nasdaq: OCX), a diagnostics technology company, today published the following letter to shareholders in conjunction with its first quarter results:
Oncocyte Reports Q1 2025 Results and Business Progress
Neutral
GlobeNewsWire
6 days ago
Oncocyte to Release First Quarter 2025 Results on May 12, 2025
IRVINE, Calif., May 07, 2025 (GLOBE NEWSWIRE) -- Oncocyte Corp., (Nasdaq: OCX), a leading diagnostics technology company, today announced that it will report first quarter 2025 financial results after the market closes on Monday, May 12, 2025.
Oncocyte to Release First Quarter 2025 Results on May 12, 2025
Neutral
MCAP MediaWire
6 days ago
Oncocyte to Release First Quarter 2025 Results on May 12, 2025
IRVINE, Calif., May 7, 2025 – PRISM MediaWire – Oncocyte Corp., (Nasdaq: OCX), a leading diagnostics technology company, today announced that it will report first quarter 2025 financial results after the market closes on Monday, May 12, 2025.
Oncocyte to Release First Quarter 2025 Results on May 12, 2025
Positive
Zacks Investment Research
1 week ago
Best Momentum Stocks to Buy for May 6th
MAIA, BYRN and OCX made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on May 6, 2025.
Best Momentum Stocks to Buy for May 6th
Positive
Zacks Investment Research
1 week ago
New Strong Buy Stocks for May 6th
MAIA, BYRN, OCX, BBVA and HMY have been added to the Zacks Rank #1 (Strong Buy) List on May 6, 2025.
New Strong Buy Stocks for May 6th
Neutral
GlobeNewsWire
2 weeks ago
Oncocyte Provides Positive Update on Clinical Trial Progress
IRVINE, Calif., April 30, 2025 (GLOBE NEWSWIRE) -- Oncocyte Corp., (Nasdaq: OCX), a leading diagnostics technology company, today provided a positive update on its substantial progress toward initiating its clinical trial, which is a major step required to obtain regulatory authorization to deliver an organ transplant rejection monitoring test kit to the market.
Oncocyte Provides Positive Update on Clinical Trial Progress
Neutral
GlobeNewsWire
2 weeks ago
Oncocyte's Proprietary Assay Demonstrates Long-Term Clinical Validity
Robust data set of 131 patients with 151 kidney biopsies enrolled over four years at Charité University in Berlin Supports market expansion for testing of high-risk patient population New findings advance understanding of the biology of organ rejection IRVINE, Calif., April 29, 2025 (GLOBE NEWSWIRE) -- Oncocyte Corp., (Nasdaq: OCX), a leading diagnostics technology company, today announced the publication of new and positive data regarding its proprietary blood-based transplant rejection assay.
Oncocyte's Proprietary Assay Demonstrates Long-Term Clinical Validity
Positive
Zacks Investment Research
2 weeks ago
New Strong Buy Stocks for April 24th
YARIY, OCX, SMHI, VTMX and BANF have been added to the Zacks Rank #1 (Strong Buy) List on April 24, 2025.
New Strong Buy Stocks for April 24th
Positive
Zacks Investment Research
1 month ago
OncoCyte (OCX) Upgraded to Buy: What Does It Mean for the Stock?
OncoCyte (OCX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
OncoCyte (OCX) Upgraded to Buy: What Does It Mean for the Stock?
Charts implemented using Lightweight Charts™